HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bevan, J. A. Articles by Barnett, B. L. Search for Related Content PubMed PubMed Citation Articles by Bevan, J. A. Articles by Barnett, B. L.

Tc-99m HMDP (Hydroxymethylene Diphosphonate): A Radiopharmaceutical for Skeletal and Acute Myocardial Infarct Imaging. II. Comparison of Tc-99m Hydroxymethylene Diphosphonate (HMDP) with Other Technetium-Labeled Bone-Imaging Agents in a Canine Model

Miami Valley Laboratories, The Procter & Gamble Company, Cincinnati, Ohio

Correspondence: For reprints contact: Andrew J. Tofe, PhD, Miami Valley Laboratories, P.O. Box 39175, Cincinnati, OH 45247.

ABSTRACT

Technetium-99m hydroxymethylene diphosphonate (Tc-HMDP) was compared with the two other diphosphonates (Tc-MDP and Tc-HEDP) and Tc-99m pyrophosphate (Tc-PPI) in a canine model of acute myocardial infarction. The TC-HMDP showed higher uptake in infarcted myocardium than the other two diphosphonates, and uptake equivalent to that of Tc-PPI.